Salvage Irreversible Electroporation for Refractory Locally Advanced Pancreatic Cancer: Safety and Survival Outcomes

In a retrospective study of 30 patients with refractory locally advanced pancreatic cancer, irreversible electroporation (IRE) achieved median overall survival 11.4 months (IQR 6-28) and 12.1% serious adverse events. Subsequent chemotherapy extended overall survival to 20.4 mont…

• Retrospective, single-center cohort of 30 patients with locally advanced pancreatic cancer progressing after chemotherapy and/or radiation treated with percutaneous or surgical IRE.
• When IRE was followed by additional chemotherapy, median overall survival reached 20.4 months (exact confidence interval not reported in source).
• Small sample, single-center retrospective design with likely selection bias limit generalizability; no external validation.

RadPigeon summaries are original and for information only. They are not clinical advice.